Objective. Opioid prescribing for chronic pain significantly contributes to opioid overdose deaths in the United States. Naloxone as a takehome antidote to opioid overdose is underutilized and has not been evaluated in the high-risk chronic pain population. The objective was to increase overdose education and naloxone distribution (OEND) to high-risk patients on long-term opioid therapy for pain by utilizing group visits in primary care.
Introduction
Since 1999, the amount of opioid analgesics sold in the United States has nearly quadrupled [1] . Deaths from prescription opioids-more than 16,000 in the United States in 2013 [2] -have also quadrupled during this time, leading to the widely accepted conclusion that these trends are linked [3, 4] .
Unsafe medication taking behaviors occur in up to 24% of patients prescribed opioids [5] , and high-risk use, including using multiple providers and pharmacies, is frequent [6] . Furthermore, the risk of overdose death increases significantly with increasing prescribed daily dosage [7] [8] [9] , with a hazard ratio for fatal overdose of 7.18 for patients with chronic pain prescribed 100 mg/d morphine equivalent daily dose (MEDD) or more compared with doses of 1-20 mg/d [7] . Overdose risk also increases with combined use of opioids and benzodiazepines [8, 10] , with rates of overdose death among those coprescribed benzodiazepines and opioids up to 10 times higher than that among those prescribed opioids alone [8] . Alarmingly, a recent study indicates that nearly all patients continue to receive prescription opioids after an overdose, with 7% of patients experiencing a subsequent overdose [11] . US veterans with comorbid mental health conditions are more likely to exhibit high-risk opioid use [12] , which is concerning given the high prevalence of mental health conditions in this population [13] .
The disturbing trend in fatal overdose from prescription opioids highlights the critical need for implementation of effective interventions. Naloxone, an opioid antagonist, has proven efficacy in preventing death from overdose, with few serious side effects [14] . Opioid education and naloxone distribution (OEND) programs can significantly reduce deaths in communities where they are deployed [15] . In May 2015, the US Department of Veterans Affairs (VA) developed guidelines for OEND program dissemination and suggested that primary care providers-prescribers of the vast majority of opioids in the VA-offer naloxone kits to veterans "who are at increased risk for opioid overdose or whose provider deems, based on their clinical judgment, that the veteran has an indication for a naloxone kit" [16] . A more recent study indicated that prescription of naloxone to primary care patients on long-term opioid therapy may reduce opioid-related adverse events [17] . Despite these recommendations, significant barriers to broader implementation of OEND remain. When surveyed, few primary care providers were knowledgeable about naloxone [18] . Though more recent evidence suggests increasing support of its use, providers voiced significant hesitation about prescribing naloxone, emphasizing both logistical and attitudinal barriers [19, 20] . Naloxone in primary care has been available for use at the VA Connecticut Healthcare System's (VACHS) West Haven campus since May 2015, though prior to our intervention in July 2015, only one prescription had been issued to a patient prescribed opioids in primary care. Stakeholders recognized a need to change the approach to OEND implementation to increase access for high-risk patients prescribed opioids in primary care. A group format was decided upon due to past success in providing rapid and effective treatment to patients in the primary care setting [21] [22] [23] . To facilitate OEND among patients with chronic pain at elevated risk of opioid overdose, this quality improvement project utilized group visits in the primary care setting.
Methods
The Human Subjects Subcommittee of the VACHS Investigational Review Board deemed this a quality improvement project and not human subject research project.
Intervention
Stakeholders from primary care, psychiatry, and pharmacy met to provide input on the design of the intervention. The consensus-based intervention flow was as follows: In one multiprovider primary care clinic, eligible patients were identified using the Opioid Therapy Risk Report (OTRR), a point-of-care registry of patients prescribed long-term opioid analgesics. This registry allows for systematic identification of the target population of long-term opioid users, those defined as high-risk for opioid overdose based on previously published literature: patients prescribed 100 mg MEDD or coprescribed opioids and benzodiazepines. This registry also tracks data on dispensed naloxone kits. Long-term opioid use for chronic pain was defined as having an active opioid prescription for at least 90 days in the prior six months.
At the West Haven Campus, primary care is divided into two separately functioning multiprovider clinics, with similar patient populations. This creates a natural separation into an intervention setting in one clinic and care as usual in the other. There was no formal attempt to construct a "control arm," though the natural separation of the two clinics permitted comparison.
Prior to implementation of this project, as part of a facility-wide intervention, primary care providers in both clinics received identical education regarding OEND, consisting of a one-hour educational session about naloxone delivered in our monthly primary care provider meeting. Attendance was encouraged but not mandatory. Primary care teams in the intervention setting were provided a list from the OTRR registry of all their patients prescribed opioids stratified by MEDD and by opioid/benzodiazepine coprescription, which included whether they had received a naloxone kit.
Teams in the intervention clinic were then encouraged via several emails to invite high-risk patients (those on >100 MEDD or coprescribed benzodiazepines or thought by the primary care physician to be at high risk) to the group visit via a scripted phone call from a health technician. To ensure equitable access to the group visit and to ensure all patients on long-term opioid therapy had the opportunity to learn more about risk reduction strategies, everyone on long-term opioid therapy in the intervention clinic was sent a letter inviting them to participate. Patients on 50-100 mg MEDD, those on other nonbenzodiazepine sedating medications, and those with other comorbidities such as obstructive sleep apnea were not included in our "high-risk" category, though they are still at increased risk for overdose. Hence, we felt it was important to allow all patients access to this intervention.
The content and structure of the group visit was adapted from a similar OEND program used in outpatient substance use clinics. A multidisciplinary team of clinicians and researchers tailored the program to terminology and issues more applicable to patients prescribed opioids for chronic pain. For example, the importance of dosage on overdose risk as well as comorbidities that might elevate risk was highlighted. Led by a primary care physician, the group visit focused on patient-centered strategies for 1) reducing risks of overdose; 2) recognizing symptoms of opioid overdose; and 3) responding to an overdose (including administration of naloxone). Teaching included a short PowerPoint presentation (27 slides), from which patients were provided a print-out of slides to take notes on, a hands-on demonstration of use of a naloxone auto-injector (EVZIO), and a question/answer period. The group visits were capped at 10 participants and lasted approximately 90 minutes. The naloxone kit was prescribed at the end of the visit, with participants having the option to fill the prescription at the on-site pharmacy. The outof-pocket cost for veterans for a kit (which includes a trainer, as well as two active naloxone autoinjectors) was $9.00. On completion of the group visit, patients were given a brief satisfaction survey on their experience with the visit.
Fisher's exact test was used to compare naloxone prescription in the intervention clinic with the usual care clinic.
Results
A total of 277 patients (3.9%) within the intervention clinic received long-term opioids for chronic pain, compared with a total of 224 patients (3.0%) in the usual care clinic; 87 patients (1.2%) in the intervention clinic were considered at high risk for overdose compared with 91 patients (1.2%) in the usual care clinic (Figure 1 ). Eight months after roll out, the intervention clinic completed six group visits, attended by a total of 24 patients, with 24 naloxone prescriptions written, all of which were filled. We did not track how frequently family members/friends attended, though the invitation to attend the group encouraged this. This compares with three naloxone prescriptions provided and filled in the usual care clinic. With respect to the higher-risk subset, 27% of patients received naloxone in the intervention clinic, compared with 3.3% in usual care clinic (Figure 2) . Likelihood of naloxone prescription fill was strongly correlated with group visit attendance, and this finding has persisted over time (Figure 3) . The provision of naloxone between these two groups was analyzed using a Fisher's exact test, yielding P < 0.0001.
Twelve of 14 providers in the intervention clinic had patients attend the group. No-show rates for the group were approximately 20-30%. Among patients attending the group, the average MEDD was 128 mg, and eight (33%) were coprescribed benzodiazepines. Via the brief survey, all patients indicated they would recommend the group visit to others and uniformly provided positive feedback regarding its utility.
Discussion
In this quality improvement project implementing group visits for OEND among high-risk patients on long-term opioid therapy for chronic pain, we identified a successful model that could be adopted in other similar primary care settings. It appropriately targeted high-risk patients, as evidenced by the high MEDD and high rates of benzodiazepine coprescription in patients receiving naloxone. The group visit format was significantly more successful in dissemination of naloxone compared with care as usual. At these group visits, patients were engaged, valued the experience, and all requested prescriptions for the naloxone kit, suggesting the small out-of-pocket cost for veterans was not a barrier. Outside of the VA, intranasal naloxone is typically much less expensive than the auto-injector; according to the manufacturer for NARCAN nasal spray, 73% of prescriptions have a copay of $10 or less. Out-of-pocket expense is variable for the nose spray, with costs ranging from $10 to $50 [24] . The prices for auto-injector kits have risen significantly, with out-of-pocket prices now ranging higher than $2,000, which may limit broader access [25] . While a larger implementation study would be needed to confirm, our pilot program offering OEND group visits outperformed provider education without access to group visits. Importantly, one can argue that targeting attitudinal barriers with education alone was insufficient to improve uptake, as few prescriptions were generated in the absence of a group visit. This supports the importance of addressing logistical barriers to naloxone delivery.
Overall, designing and implementing the group visit within our practice setting required relatively little time and effort; an average of 22.5 minutes of physician time was spent per patient attending the group, in addition to physician and health technician coordination time. This low investment was likely due to the fact that other group visits for conditions such as diabetes and opioid/ chronic pain education have been implemented at our site. Recent systems-level improvements (e.g., availability of the OTRR) facilitated identification of highrisk patients directly by the team, permitting a team approach to engagement strategies. However, increasing eligible patient attendance in the intervention group was challenging, requiring modifications that targeted both clinicians and patients such as list distribution and proactive e-mail reminders to clinicians, as well as a letter to patients informing them about the group. Only a small percentage of patients responded to recruiting efforts, highlighting the need for qualitative data from patients on barriers and facilitators.
Future refinements of the QI approach will focus on assessing and mitigating patient barriers to attendance in OEND group visits, better use of the OTRR population health registry directly by the care team, and leveraging the patient's whole team to work on engagement strategies. Future directions include dissemination and further study of implementation of a group visit format for OEND in primary care. Previous studies have demonstrated the efficacy of nurse practitioner-led group visits [26] ; modification of the OEND group format to be led by a nonphysician practitioner could expand its feasibility in other settings.
This project adds to previous research by demonstrating that group visits in primary care for chronic conditions are efficacious and satisfactory to patients [21] [22] [23] . In a survey of primary care practitioners, half reported time pressure during patient visits and a chaotic work pace [27] ; implementing group visits has emerged as an effective tool to address the ever-present challenge of delivering high-quality care to patients with complex chronic illnesses [23] . Additionally, the VA has recognized the possibilities of this format, and in 2005 mandated shared or group medical appointments as a means to improve clinic efficiency and quality of care [28] . Limitations include the small sample size, lack of a definitive outcome measure such as opioid-related overdoses and/or deaths, and lack of long-term data to provide evidence that this format can persist and spread beyond this site. As this was a quality improvement study, patients could not be randomized, and a quasiexperimental design was used. The patients included in this study were all veterans, limiting generalizability to non-VA settings. Future studies should be larger, more rigorous, and better powered to assess outcome data. Assessments could include knowledge and attitude measures. Future research is needed on the long-term feasibility, applicability, and efficacy in other settings and the cost-effectiveness of group interventions.
Conclusion
We showed group visits for OEND in primary care to be a promising format for provision of naloxone kits to high-risk patients taking chronic opioids for pain. Patients were satisfied with this format of care, and it resulted in significantly higher provision of naloxone kits than usual care. Further dissemination and adaptation will determine wider feasibility and generalizability.
